Alopecia secondary to anti-tumor necrosis factor-alpha therapy

Citations of this article
Mendeley users who have this article in their library.


Biologic drugs represent a substantial progress in the treatment of chronic inflammatory immunologic diseases. However, its crescent use has revealed seldom reported or unknown adverse reactions, mainly associated with anti-tumor necrosis factor (anti-TNF). Psoriasiform cutaneous reactions and few cases of alopecia can occur in some patients while taking these drugs. Two cases of alopecia were reported after anti-TNF therapy. Both also developed psoriasiform lesions on the body. This is the second report about a new entity described as 'anti- TNF therapy-related alopecia', which combines clinical and histopathological features of both alopecia areata and psoriatic alopecia. The recognition of these effects by specialists is essential for the proper management and guidance of these patients.




Ribeiro, L. B. P., Rego, J. C. G., Duque Estrada, B., Bastos, P. R., Maceira, J. M. P., & Sodré, C. T. (2015). Alopecia secondary to anti-tumor necrosis factor-alpha therapy. Anais Brasileiros de Dermatologia, 90(2), 232–235.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free